P-1262. Safety and Pharmacokinetics of Ainuovirine, a Novel Non-NucleosideReverse Transcriptase Inhibitor, in Healthy Chinese Adults
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.1444
Abstract: Abstract Background Ainuovirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for treatment of human immunodeficiency virus type 1 (HIV-1) infection. The safety profile and pharmacokinetics of ainuovirine was characterized in healthy adults administered with… read more here.
Keywords: dose; transcriptase inhibitor; time; ainuovirine novel ... See more keywords
Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.17411
Abstract: An elevated activity of retrotransposons is increasingly recognized to be implicated in a wide range of neurodegenerative and neurodevelopmental diseases. Down syndrome (DS) is the most common genetic disorder associated with intellectual disability and a… read more here.
Keywords: reverse transcriptase; reverse; model; lamivudine reverse ... See more keywords
Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study
Sign Up to like & getrecommendations! Published in 2022 at "Antiviral Therapy"
DOI: 10.1177/13596535221077487
Abstract: Background In the DAWNING study, dolutegravir + 2 nucleoside reverse transcriptase inhibitors (NRTIs) demonstrated superior efficacy at Week 48 and a favourable safety profile compared with lopinavir/ritonavir + 2 NRTIs in adults with HIV-1 failing… read more here.
Keywords: nucleoside reverse; reverse transcriptase; transcriptase inhibitor;